Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. have settled with plaintiffs in the first three federal cases scheduled for trial over whether Abilify caused their gambling urges.
There are about 800 Abilify cases in federal multidistrict proceedings in the U.S. District Court for the Northern District of Florida.
Plaintiffs allege the companies knew or should have known the anti-psychotic medication causes uncontrollable gambling and other impulsive behavior, yet failed to warn patients or the medical community in the U.S.
The first three trials had been set to start in June.
They were resolved following mediation with a settlement master, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.